Ramon Alemany is the leader of the Cancer Virotherapy Group in Oncobell, which explores new anticancer treatments based on oncolytic adenoviruses. The group aims to design and evaluate oncolytic adenoviruses as antitumour agents for various solid tumours. The main lines of research are tumour targets, intratumoural diffusion through stromal barriers and oncolytic immunotherapy. The group also participates in other immunotherapy projects based on mutanome-derived cancer neoepitopes.

Ramon Alemany is going to talk about Potential and limitations of oncolytic adenoviruses in the first symposium organized by Oncobell.

Leave a reply